Resveratrol cancer study
This article was originally published in The Tan Sheet
Executive Summary
NCI-funded trial on red wine compound for cancer prevention will begin in January at England's University of Leicester with $1.7 mil. grant. Sequential trial features three phases: healthy volunteers will receive one-time 500 mg dose so researchers can measure blood levels of resveratrol, determine cancer fighting markers and doses for remainder of study. Second healthy group will receive daily resveratrol for 28 days with similar endpoints. In third group, patients with colon tumors will be dosed seven days prior to surgery, with tumor material tested for drug levels post-op. Leicester's U.S. partner University of Michigan will host some trial activity. Study completion expected by 2004...